Northwest gains on GBM survival data

Northwest Biotherapeutics Inc. (NASDAQ:NWBO) reported data from glioblastoma multiforme (GBM) patients who were ineligible for enrollment in the company's ongoing Phase III trial of DCVax-Brain ( DCVax-L), and instead were treated in a separate study arm. In that "informational arm," DCVax-Brain (DCVax-L) led to a median overall survival of 18.3 months in 51 GBM patients whose tumors showed evidence of regrowth following six weeks of radiation and chemotherapy.

Northwest spokesperson Jane Searle declined to say when the company expects data from its Phase III trial of the autologous dendritic cells treated ex vivo with glioblastoma tumor fragments. Searle said data from the informational arm cannot be included in regulatory submissions. ...